Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

818.22 +12.99 (+1.61%)
Official Closing Price Updated: 4:10 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Via Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In December 2024 — Where Do Tesla, Nvidia, Quantum Computing Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Is Eli Lilly an Undervalued Growth Stock to Buy Now?
Via The Motley Fool
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead. 
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca 
Via MarketBeat
Exposures COVID-19
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
The world's richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. 
Via Benzinga
Prediction: This Will Be Amazon's Next Big Acquisition
Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years. 
Via The Motley Fool
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Elon Musk sparked conversation about weight-loss drugs and side effects with a Christmas social media post. 
Via Benzinga
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors. 
Via The Motley Fool
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Via The Motley Fool
1 Spectacular Growth Stock That Could Join Nvidia, Tesla, Apple, and Others in the $1 Trillion Club
Via The Motley Fool
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
Eli Lilly Stock Is Rising Monday: What's Going On?
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat... 
Via Benzinga
Exposures Product Safety
3 Big-Name Stocks Just Announced Big-Time Dividend Increases
Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments. 
Via MarketBeat
Topics ETFs
Better Buy: Eli Lilly or Novo Nordisk?
Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results. 
Via The Motley Fool
Does This News From the FDA Make Eli Lilly a Buy for 2025?
Via The Motley Fool
Exposures Product Safety
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Is Merck the Next Big Weight-Loss Stock?
Via The Motley Fool
3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year
Via The Motley Fool
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans. 
Via Benzinga
Exposures Product Safety
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
Via The Motley Fool
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off. 
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.